Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 6, 2013, Pages

  Lands, Larry C ^a   Stanojevic, Sanja ^b  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; IBUPROFEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; SULFONAMIDE;

ABDOMINAL PAIN; BODY WEIGHT CHANGE; BRAIN HEMORRHAGE; BRONCHOSPASM; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; CONJUNCTIVITIS; CYSTIC FIBROSIS; DIARRHEA; DISEASE EXACERBATION; DRUG EFFICACY; DYSPEPSIA; EPIGASTRIC PAIN; EPISTAXIS; FECES ANALYSIS; FEVER; FORCED EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEPATITIS; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; IDEAL BODY WEIGHT; LENGTH OF STAY; LUNG DISEASE; NAUSEA; NUTRITIONAL STATUS; OCCULT BLOOD; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RASH; REACTIVE ARTHRITIS; REFLUX ESOPHAGITIS; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; THORAX RADIOGRAPHY; TINNITUS; VOMITING; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLARITHROMYCIN; CYSTIC FIBROSIS; HUMANS; IBUPROFEN; PIROXICAM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONAMIDES;

EID: 84891719351     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001505.pub3     Document Type: Review

References (31)

1. Konstan MW, Hoppel CL, Chai B, Davis PB. Ibuprofen in children with cystic fibrosis: pharmacokinetics and adverse effects. Journal of Pediatrics 1991;118(6):956-64.
2. Konstan MW. Systemic anti-inflammatory treatment NSAID [abstract]. Proceedings of the 20th European Cystic Fibrosis Conference; 1995 June 18-21; Brussels, Belgium. 1995:L51.
3. Konstan MW, Byard PJ, Hoppel CL, Davis PB. Effect of high-dose ibuprofen in patients with cystic fibrosis. New England Journal of Medicine 1995;332(13):848-54.
4. Konstan MW, Davis PB, Byard PJ, Hoppel CJ. Results of a four-year, randomized, placebo-controlled, double-blind trial of high-dose ibuprofen in CF patients with mild lung disease [abstract]. Pediatric Pulmonology 1994;Suppl 10:S6.4.
5. Lands LC, Corey M, Milner R, Kilcullen A, Cantin AM. High dose ibuprofen in CF children: the Trans-Canadian trial [abstract]. Pediatric Pulmonology 2002;34(Suppl 24):276.
6. Lands LC, Milner R, Cantain AM, Manson D, Corey M. High-dose Ibuprofen in Cystic Fibrosis: Canadian Safety and Effectiveness Trial. Journal of Pediatrics 2007;151(3):249-54.
7. Pukhalsky AL, Shmarina GV, Kaproanov NI, Kashirskaja NJ, Kokarovtseva SN, Shabalova LA, et al.Increase of the sputum neutrophil elastase activity is a paradoxical effect of the successful lung disease treatment in cystic fibrosis [abstract]. Pediatric Pulmonology 2001;32(Suppl 22):274.
8. Shmarina GV, Pukhalsky AL, Kashirskaja NJ. Anti-inflammatory therapy in cystic fibrosis: a comparative study in the treatment with nimesulide (selective cyclooxygenase-2 inhibitor) and clarithromycin (14-memebered ring macrolide antibiotic) [abstract]. European Respiratory Journal 2004;24(Suppl 48):P3758.
9. Sordelli DO, Macri CN, Maillie AJ. A study on the effect of Piroxicam (PIR) treatment to prevent lung damage in CF patients with Pseudomonas aeruginosa (Psa) pneumonia [abstract]. Pediatric Pulmonology 1990;Suppl 5:215.
10. Sordelli DO, Macri CN, Maillie AJ, Cerquetti MC. A preliminary study of the effect of anti-inflammatory treatment in cystic fibrosis patients with pseudomonas aeruginosa lung infection. International Journal of Immunopathology and Pharmacology 1994;7(2):109-17.
11. Chmiel JF, Konstan MW, Lymp J, Mayer-Hamblett N, Hilliard KA, Accurso FJ, et al.Assessment of induced sputum as a tool to evaluate anti-inflammatory agents in CF [abstract]. Pediatric Pulmonology 2007;42(Suppl 30):228.
12. Kovaleva LF, Guembitskaia TE, Gorbenko IA, Aleshin YuN. Combined systemic enzymotherapy and nebulizer therapy in the management of cystic fibrosis (CF) patients [abstract]. 13th International Cystic Fibrosis Congress; 2000 June 4-8; Stockholm, Sweden. 2000:155.
13. Noritake D, Hen J, Dolan TF. Effects of aspirin on pulmonary function in patients with cystic fibrosis [abstract]. Proceedings of the 22nd Annual Meeting Cystic Fibrosis Club Abstracts; 1981 May 1; San Francisco, California. 1981:144.
14. Noritake DT, Hen J, Leo L, Dolan TF. The influence of aspirin on lung function in cystic fibrosis. Connecticut Medicine 1982;46:574-6.
15. Bertenshaw C, Watson A, Lewis S, Smyth A. A survey of acute renal failure in cystic fibrosis patients in the United Kingdom. http://thorax.bmj.com/ (accessed 30 January 2007).
16. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clinical Reviews in Allergy & Immunology 2002;23(1):5-27.
17. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal Respiratory and Critical Care Medicine 2003;168(8):918-51.
18. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
19. Konstan MW, Vargo KM, Davis PB. Ibuprofen attenuates the inflammatory response to Pseudomonas aeruginosa in a rat model of chronic pulmonary infection. American Review of Respiratory and Critical Care Medicine 1990;141(1):186-92.
20. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatric Pulmonology 1997;24(2):137-42.
21. Konstan MW. Personal Communication 1999.
22. Konstan MW, Krenicky JE, Finney MR, Kirchner HL, Hilliard KA, Hilliard JB, et al.Effect of ibuprofen on neutrophil migration in vivo in cystic fibrosis and healthy subjects. Journal of Pharmacology and Experimental Therapeutics 2003;306(3):1086-91.
23. Konstan MW, Schluchter MD, Xue W, Davis PB. Clinical use of Ibuprofen is associated with slower FEV1 decline in children with cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2007;176(11):1084-9.
24. Kovesi TA, Swartz R, MacDonald N. Transient renal failure due to simultaneous ibuprofen and aminoglycoside therapy in children with cystic fibrosis (letter). New England Journal of Medicine 1998;338(1):65-6.
25. Li J, Xiang YY, Ye L, Tsui LC, Macdonald JF, Hu J, et al.Nonsteroidal anti-inflammatory drugs upregulate function of wild-type and mutant CFTR. European Respiratory Journal 2008;32(2):334-43.
26. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: a consensus statement. Cystic Fibrosis Foundation Consensus Panel. Journal of Pediatrics 1998;132(4):589-95.
27. Southern KW, Barker PM, Solis A. Macrolide antibiotics for cystic fibrosis. Cochrane Database of Systematic Reviews 2004, Issue 3. [DOI: 10.1002/14651858.CD002203.pub2]
28. Wheeler WB, Williams RN, Matthews WJ, Colten HR. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. Journal of Pediatrics 1984;104(5):685-99.
29. Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 1999, Issue 2. [DOI: 10.1002/14651858.CD001505]
30. Lands LC, Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001505]
31. Lands LC, Stanojevic S. Oral non-steroidal anti-inflammatory drug therapy for lung disease in cystic fibrosis. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD001505.pub2]